Similar observations were described for PD-1 and PD-L1 inhibitor-treated NSCLC patients with strong sPD-L1 elevation in some cases, while in tyrosine kinase inhibitor-treated NSCLC cases, no such increase could be observed [40]. This evidence concerns the gene SPDL1 and non-small cell lung carcinoma.